Newsmeme!
Discover News you didn't know existed
Follicular Phase
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
ZEVALIN® Data to Be Presented at 2008 Annual Meeting of the American Society of Hematology
Published December 4, 2008, 4:00 am, Business Wire via Yahoo! Finance
IRVINE, Calif.----Spectrum Pharmaceuticals, Inc. today announced that ZEVALIN® related posters and presentations will be presented at the 50th Annual Meeting of the American Society of Hematology , December 5-9, 2008 in San Francisco, California.
Zevalin Data to be Presented at ASH 2008
Published December 3, 2008, 10:30 pm, PR Newswire via Yahoo! Finance
Cell Therapeutics, Inc. today announced presentations or posters of interest related to Zevalin® to be presented at the 50th Annual Meeting of the American Society of Hematology , December 5-9, 2008 in San Francisco.
U.S FDA Grants Pralatrexate Orphan Drug Designation For The Treatment Of Patients With Follicular Lymphoma
Published December 2, 2008, 9:13 am, Medical News Today
Allos Therapeutics, Inc. (Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to the Company's novel antifolate, pralatrexate (PDX), for the treatment of patients with follicular lymphoma.
FDA accepts Zevalin supplemental biologics license application
Published December 2, 2008, 2:51 am, News-Medical-Net
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line ...
Hormones: Learning the rules of attraction
Published December 2, 2008, 2:08 am, Independent
A woman's smile may not be all it seems. When her zygomaticus major cheek muscle moves the upper lip upward and outward to produce that warm smile, it may be more than a friendly gesture – it could be a sign of hormones at work.
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
Published December 1, 2008, 1:00 pm, Business Wire via Yahoo! Finance
WESTMINSTER, Colo.----Allos Therapeutics, Inc. , a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S.
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Date of ...
Published December 1, 2008, 4:19 am, Centre Daily Times
Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC)(MTA:CTIC), received notice that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for the supplemental Biologics License Application (sBLA) for use of ZEVALIN® ([ 90 ...
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Date of ...
Published December 1, 2008, 4:00 am, Business Wire via Yahoo! Finance
IRVINE, Calif.----Spectrum Pharmaceuticals, Inc. today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. , received notice that the U.S. Food and Drug Administration has accepted for filing and review, and has granted priority review status for the supplemental Biologics License Application for use of ZEVALIN® as first line consolidation therapy for patients with ...
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Published November 30, 2008, 10:30 pm, PR Newswire via Yahoo! Finance
Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application for use of Zevalin® as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |